Remission maintenance therapy for meningeal leukemia: intrathecal methotrexate vs. intravenous bis-nitrosourea.
D000293:Adolescent; D001856:Bone Marrow Examination; D002648:Child; D002675:Child, Preschool; D005334:Fever / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007275:Injections, Intravenous; D007278:Injections, Spinal; D007938:Leukemia / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008578:Meninges; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D009443:Neuritis / Q000139:chemically induced; D009603:Nitroso Compounds / Q000008:administration & dosage* / Q000009:adverse effects; D012075:Remission, Spontaneous; D014508:Urea; D014839:Vomiting / Q000139:chemically induced
D009603:Nitroso Compounds; D014508:Urea; D008727:Methotrexate